Recent News

• 04.24.2025 - Ono Pharma Announces an Oral Presentation on Phase 2 Data for Tirabrutinib and a Poster Session on ONO-4578 (EP4 Antagonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting
• 03.12.2025 - Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
• 08.15.2024 - U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
• 08.15.2024 - U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
• 07.19.2024 - European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
• 07.19.2024 - European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
• 07.18.2024 - European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
• 06.11.2024 - Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
• 06.11.2024 - Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
• 06.11.2024 - Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

Recent Filings

• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.21.2024 - 15-12G Securities registration termination [Section 12(g)]
• 06.13.2024 - EFFECT Notice of Effectiveness
• 06.11.2024 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2024 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2024 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 06.11.2024 - 4 Statement of changes in beneficial ownership of securities